Contravisory Investment Management Inc. Reduces Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

Contravisory Investment Management Inc. reduced its holdings in Axon Enterprise, Inc. (NASDAQ:AXON) by 11.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 722 shares of the biotechnology company’s stock after selling 96 shares during the period. Contravisory Investment Management Inc.’s holdings in Axon Enterprise were worth $429,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Geode Capital Management LLC grew its position in shares of Axon Enterprise by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,782,828 shares of the biotechnology company’s stock valued at $710,103,000 after purchasing an additional 35,320 shares in the last quarter. Westfield Capital Management Co. LP boosted its position in shares of Axon Enterprise by 12.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock valued at $469,661,000 after acquiring an additional 127,769 shares during the last quarter. Champlain Investment Partners LLC grew its holdings in shares of Axon Enterprise by 13.9% in the third quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company’s stock valued at $272,695,000 after purchasing an additional 83,265 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Axon Enterprise by 1.6% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 561,263 shares of the biotechnology company’s stock worth $224,281,000 after purchasing an additional 9,090 shares during the last quarter. Finally, Groupama Asset Managment purchased a new position in Axon Enterprise during the third quarter worth about $200,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Robert W. Baird raised their price target on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a report on Friday, December 6th. Morgan Stanley raised shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $500.00 to $700.00 in a research report on Tuesday, December 3rd. JMP Securities lifted their price target on shares of Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research report on Thursday, October 31st. Needham & Company LLC upped their price objective on shares of Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Finally, TD Cowen began coverage on shares of Axon Enterprise in a report on Wednesday, January 8th. They issued a “buy” rating and a $700.00 target price for the company. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and a consensus price target of $504.92.

Axon Enterprise Trading Up 0.0 %

NASDAQ:AXON opened at $580.00 on Thursday. Axon Enterprise, Inc. has a 12-month low of $246.99 and a 12-month high of $698.67. The firm has a market cap of $44.23 billion, a PE ratio of 149.87, a price-to-earnings-growth ratio of 5.71 and a beta of 1.04. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. The stock has a fifty day moving average price of $615.21 and a 200 day moving average price of $455.82.

Insider Buying and Selling at Axon Enterprise

In related news, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $639.69, for a total value of $639,690.00. Following the sale, the director now owns 24,259 shares of the company’s stock, valued at $15,518,239.71. This trade represents a 3.96 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of Axon Enterprise stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total transaction of $271,831.50. Following the completion of the transaction, the director now owns 6,929 shares of the company’s stock, valued at $4,185,601.03. This represents a 6.10 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,545 shares of company stock valued at $30,721,337 in the last quarter. Corporate insiders own 5.70% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.